Notably, PD-1 is a marker of effector T-cell exhaustion98, and the I-SPY 2 trial results suggest that targeting T-cell exhaustion markers may be a very productive approach in hormone receptor–positive/HER2-negative breast cancer and TNBC. This evidence concerns the gene ERBB2 and breast carcinoma.